Tatva Chintan Pharma: Strong Q2 Results Revealed! Analyst Upgrades to 'REDUCE' With INR 1,380 Target - What Investors Must Know!

Overview

Tatva Chintan Pharma Chem reported a robust Q2 FY26 with operating revenue climbing 48% year-on-year to INR 1,235 million and EBITDA soaring 298% year-on-year to INR 222 million. The strong performance, especially in the SDA segment, led analyst Deven Choksey to upgrade the stock from 'SELL' to 'REDUCE', setting a target price of INR 1,380, while noting that positives are largely factored into the current stock price.